<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002181'>Brain edema</z:hpo> is a major and often mortal complication of <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Vascular endothelial growth factor (VEGF) is also known as a potent vascular permeability factor and may play detrimental roles at the <z:hpo ids='HP_0011009'>acute</z:hpo> stage of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Our goal in this study was to explore protective effects of gene transfer of soluble flt-1 (sFlt-1), a natural inhibitor of VEGF, on focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Adenoviral vector encoding sFlt-1 or beta-galactosidase as control was injected into the lateral ventricle 90 mins after photochemical distal middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in male spontaneously hypertensive rats </plain></SENT>
<SENT sid="4" pm="."><plain>The transduced sFlt-1 was released to the cerebrospinal fluid from the ventricular wall and significantly increased 6 h, 1 and 7 days after sFlt-1 transfection </plain></SENT>
<SENT sid="5" pm="."><plain>One day after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>, sFlt-1 gene transfer significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (by 35%), <z:hpo ids='HP_0002181'>brain edema</z:hpo> (by 35%), and blood-brain barrier permeability (Evans blue extravasation; by 69%) with diminished phosphorylation of focal <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> kinase (FAKtyr397 and FAKtyr861) in the ischemic vessels </plain></SENT>
<SENT sid="6" pm="."><plain>Seven days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, sFlt-1 gene transfer also significantly attenuated <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (by 29%) and monocyte/macrophage infiltration (by 27%), although there were no reductions in <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> by sFlt-1 overexpression </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest that sFlt-1 gene therapy targeting <z:hpo ids='HP_0002181'>brain edema</z:hpo> in <z:hpo ids='HP_0011009'>acute</z:hpo> stage of <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> may be useful for <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
</text></document>